What Реквип Модутаб Treats: Main Uses and Benefits

This medication is applied in managing chronic movement and sensory disorders. The primary focus is on addressing key symptomatic domains and supports patients in maintaining functional stability. This extended-release formulation is commonly used to treat the symptoms of Parkinson’s disease. The active ingredient is also relevant for managing symptoms associated with moderate-to-severe Restless Legs Syndrome (RLS).

---

Primary Therapeutic Domains

This medicine is commonly used to help with managing the physical manifestations of Parkinson's disease, including tremor, muscle stiffness (rigidity), and the slowness of movement (bradykinesia). It is commonly used to help with managing these symptoms, which supports the patient's efforts to maintain smoother daily movement and coordination, relevant for easing symptoms that interfere with daily functioning. It may be part of symptomatic management in advanced contexts to address motor fluctuations, which assists with maintaining functional stability. Furthermore, it is relevant for easing the overwhelming, discomfort-driven urge to move the legs that characterizes RLS.

Quick Fact: Targets Slowness of Movement (Bradykinesia)

---

Key Therapeutic Benefit

In situations where chronic conditions involve episodic or fluctuating manifestations, this medicine is commonly applied to address the inconsistent motor response that can occur as the disease progresses. This supportive approach assists with maintaining functional stability and supports general well-being, particularly by managing symptoms that interfere with daily functioning and sleep.

Regulatory References

1. U.S. National Library of Medicine DailyMed overview

Eligibility: Who Can and Cannot Use Requip Modutab

The use of Реквип Модутаб (Ropinirole prolonged-release tablets) is strictly defined by regulatory eligibility criteria concerning age, physiological status, organ function, and pre-existing conditions.

---

Absolute Exclusions (Contraindications)

The medicine is contraindicated and must not be used by patients with a known hypersensitivity or allergic reaction to Ropinirole or any of the tablets' inactive ingredients. Use is also prohibited in patients with severe hepatic impairment or severe renal impairment (creatinine clearance <30 mL/min) who are not on regular hemodialysis.

---

Population and Conditional Restrictions

Population Group	Regulatory Status	Limitation
Pediatric Patients (under 18)	Not Recommended	Safety and efficacy are not established in this age group.
Pregnancy / Lactation	Not Recommended	Use should be avoided; Ropinirole may suppress milk production.
Older Adults (75+)	Conditional Use	Slower dose titration may be necessary at treatment initiation.
Psychiatric Disorders	Conditional Use	Should only be used if benefits outweigh the risk of underlying major psychiatric or psychotic disorders.

Eligibility is established for adult patients (18 years and older) for its labeled therapeutic uses. Patients with End-Stage Renal Disease (ESRD) on regular hemodialysis require a specific, reduced maximum daily dose.

Interactions with other medicines and products

Requip Modutab (ropinirole) can interact with several other medicines, supplements, and lifestyle factors. Before starting treatment, it is essential to inform your doctor of all products you are currently using, including over-the-counter drugs, vitamins, and herbal remedies. Dose adjustments may be necessary if you are taking interacting substances, or your doctor may advise against the combination.

---

Medications that Increase Ropinirole Levels

Combining ropinirole with certain medicines can prevent its proper breakdown in the body, leading to increased blood levels of ropinirole and a higher risk of side effects (such as drowsiness, nausea, or hallucinations). Examples include:

• Ciprofloxacin (a type of antibiotic)
• Fluvoxamine (used for depression and obsessive-compulsive disorder)
• Hormone Replacement Therapy (HRT) or oral contraceptives containing high-dose estrogen. If you start or stop HRT, your ropinirole dosage may need to be adjusted.

---

Medications that Decrease Ropinirole Efficacy

Other drugs, particularly those that block the action of dopamine, may reduce the effectiveness of ropinirole:

• Antipsychotic medications (Neuroleptics)
• Metoclopramide (used for nausea and certain gastrointestinal issues)

---

CNS Depressants and Alcohol

Using ropinirole with substances that cause drowsiness can worsen central nervous system (CNS) side effects, increasing the risk of sedation and falling asleep unexpectedly during the day. Avoid or use extreme caution with:

• Alcohol
• Sedatives, sleeping pills, or tranquilizers
• Antihistamines that cause drowsiness
• Opioid pain medications and muscle relaxers

---

Smoking

Cigarette smoking can decrease the effectiveness of ropinirole by speeding up its metabolism. Inform your doctor if you start or stop smoking during your treatment.

Реквип Модутаб, which contains ropinirole, is classified as a non-ergoline dopamine agonist primarily targeting post-synaptic D2-type receptors, including D2 and D3 subtypes. The highest binding affinity is exhibited at the D3 receptors.

The drug accumulates selectively within the central nervous system (CNS), particularly within the caudate-putamen system (striatum). Its mechanism involves mimicking the action of the endogenous neurotransmitter dopamine at these sites, thereby initiating signal transduction.

Upon binding, ropinirole selectively stimulates the G-protein-coupled D2-type receptors, which are linked to inhibitory G proteins ( Gi). This interaction triggers an intracellular cascade resulting in the inhibition of adenylyl cyclase (AC) activity. The downstream consequence of AC inhibition is a reduction in the intracellular concentration of cyclic AMP (cAMP).

Additionally, activation of these receptors modulates ion channel activity by inhibiting calcium channels and activating potassium channels. This collectively alters neuronal excitability and synaptic transmission in the nigrostriatal and mesolimbic pathways, resulting in system-level modulation of motor control and locomotion.

Administration and Dosing of Requip Modutab

The prolonged-release form of Ropinirole is administered orally as a tablet and is designed for a once daily frequency to provide sustained management of symptoms related to Parkinson's disease. To maintain the controlled, steady release of the active substance over 24 hours, the tablets must be swallowed whole and must not be chewed, crushed, or divided. The medicine can be taken with or without food.

---

Dosing Regimen

Therapy follows a structured titration process starting at a low initial dose, which is then gradually increased. Standard administration parameters include:

• Initial Dose: 2 mg once daily for the first one to two weeks.
• Titration: The dose is subsequently increased by 2 mg/day at weekly or longer intervals, as determined by the patient’s response.
• Maximum Dose: The maximum recommended total daily dose of the prolonged-release formulation is 24 mg.

Procedural Requirements

Discontinuation of Therapy: When the medicine is to be stopped, the dose is tapered gradually over a minimum period of seven days to prevent certain withdrawal symptoms. In the event that a daily dose is missed for one or more days, the protocol involves a complete re-titration of the dose upon recommencing treatment.

Specific Population Limits: While no specific starting dose adjustment is mandated for older adults, patients with end-stage renal disease who are on hemodialysis have a lower recommended maximum daily dose of 18 mg once daily.

Evidence for Use in Parkinson's Disease

Pivotal research exploring this medicine was conducted using designs defined by regulators, including short- to intermediate-term, double-blind Randomized Controlled Trials (RCTs) that compared the drug to an inactive substance. Researchers explored how symptoms change over time in two primary groups: adults with early PD monotherapy and those with advanced PD who were also experiencing fluctuating symptoms while receiving levodopa therapy. Outcomes monitored included change in the duration of the "off" state versus the "on" state and standardized clinical measurements of motor symptoms. Studies reported measured changes, but long-term effects are not fully established as the follow-up durations for core trials were typically limited to six months.

---

Evidence for Use in Restless Legs Syndrome (RLS)

Pivotal research for this condition was structured as short-term, placebo-controlled RCTs. These studies monitored patient-reported outcomes describing perceived discomfort and severity using the International Restless Legs Scale (IRLS), alongside objective methods like polysomnography to monitor Periodic Leg Movements during Sleep (PLMS). Studies described patterns observed in the studied populations related to the difference in measured RLS symptom severity when compared to groups receiving an inactive substance. Research provides limited insight regarding the long-term patterns associated with this class of medication, such as augmentation, and comparative evidence for differences in outcomes between the prolonged-release and immediate-release versions is lacking.

---

Long-Term Studies and Durability of Follow-up

Follow-up durations were limited in the core trials. While initial short-term RCTs provided insight into short-term changes, the data are still emerging when assessing long-term effects. Longer-term data, sometimes extending up to one year, was provided by open-label studies. However, evidence quality varies across studies when moving from the double-blind, placebo-controlled setting to extension studies, meaning the persistence of reported outcomes is not fully established.

---

Evidence in Specific Patient Groups

The results apply only to the populations studied, which were primarily general adult cohorts. Data for certain groups remain insufficient, including those with significant additional health conditions (comorbidities) or paediatric populations, as these groups are often excluded from the core regulatory trials to ensure homogeneity of the studied population.

---

Research Gaps and Areas of Uncertainty

Follow-up durations were limited in the core trials, meaning long-term outcomes are not fully established. Comparative evidence is lacking to definitively determine differences in outcomes or long-term patterns when comparing the prolonged-release formulation to the immediate-release version, particularly in RLS. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole (NCT00314860 - RLS Comparator Trial)

Common questions about Реквип Модутаб (FAQ)

---

Q: Does Requip Modutab interact with any foods or drinks?

Official regulatory documents state that the medication can be taken with or without food. However, it is important to be aware that substances that increase drowsiness, such as alcohol, should generally be avoided. This is because combining them increases the risk of central nervous system (CNS) side effects like excessive sedation.

---

Q: How should I store Requip Modutab tablets in my home?

According to the official product information, these tablets must be kept in their original container to protect them from light and moisture. Storage should be at a controlled room temperature, typically meaning not exceeding 25 C (77 F).

---

Q: Can Requip Modutab be used to treat restless legs syndrome in children?

Regulatory documents state that the safety and effectiveness of this medicine have not been established in pediatric patients, who are defined as individuals under 18 years of age. Therefore, the medication is not recommended for use in this age group for any condition.

---

Q: What should I do if I miss a dose of Requip Modutab?

The official labeling indicates that if therapy is interrupted for one or more days, a complete re-titration of the dose may be required, as determined by a healthcare provider. The product information does not provide specific instructions for managing a single missed dose of the prolonged-release tablet, so patients should consult their healthcare provider for guidance.

---

Q: What are the symptoms of an overdose of Requip Modutab?

Symptoms of an overdose are related to the medicine's effects as a dopamine agonist. Regulatory documents list potential signs of overdose, which include intense nausea, vomiting, dizziness, somnolence (drowsiness), and a drop in blood pressure when standing (postural hypotension).

How to Store and Dispose of Requip-Modutab

Official regulatory documents define specific conditions for the storage and handling of Requip-Modutab prolonged-release tablets to ensure product integrity.

Mandatory Storage Conditions

Requirement	Official Instruction
Temperature	Store at controlled room temperature, not above 25 C (77 F).
Container Protection	Store in the original package and keep the container tightly closed.
Environment	The product must be protected from light and moisture.
Child Safety	Keep the medicine out of the reach and sight of children.

Disposal Instructions

Regulatory labeling states there are no special product-specific requirements for disposal. Any unused, expired, or waste material must be discarded in accordance with local regulations.